At Leading Edge Physiotherapy, we are committed to providing innovative, evidence-based treatments to improve quality of life for those affected by chemotherapy-induced peripheral neuropathy (CIPN).
This article explores the use of the Stimpod NMS460 device, a cutting-edge tool in our arsenal for managing this challenging condition. We’ll cover what CIPN is, a detailed explanation of the Stimpod, how it’s applied in our clinics, treatment protocols, costs, insurance considerations, and the latest on safety and efficacy, supported by research references.
Understanding Chemotherapy-Induced Peripheral Neuropathy (CIPN)
CIPN is a common side effect of cancer treatments, affecting up to 68% of patients receiving neurotoxic chemotherapies like platinum-based drugs (e.g., oxaliplatin) or taxanes (e.g., paclitaxel).
It results from damage to peripheral nerves, leading to symptoms such as:
- Burning pain
- Tingling
- Numbness
- Cramping
- Weakness in the hands and feet
These symptoms can persist long after treatment ends, impacting daily activities, mobility, and overall well-being. While natural recovery may occur over months, many patients experience chronic issues. Non-pharmacological interventions, including electrotherapy, have shown promise in alleviating these symptoms by modulating nerve function and reducing inflammation (Gewandter et al., 2019).
What Is the Stimpod NMS460 Device?
The Stimpod NMS460 is an FDA-cleared, non-invasive neuromodulation device developed by Algiamed Technologies.
- Combines low-frequency electrical currents for nerve mapping with pulsed radiofrequency (PRF) waves (100–500 kHz) to create a therapeutic electromagnetic field.
- Unlike traditional transcutaneous electrical nerve stimulation (TENS), which primarily masks pain, the Stimpod targets the root cause by delivering a hybrid waveform transdermally—through the skin—without needles or surgery.
The device features a pen-shaped probe that applies ultrasound gel for conductivity. Low-frequency currents (up to 20mA) help locate affected nerves by eliciting muscle twitches or sensory responses, ensuring precise targeting.
Once located, the PRF component generates a non-thermal field that travels along the nerve to the spinal cord and brain. This triggers a metabolic cascade, influencing gene expression related to inflammation reduction and nerve regeneration. Clinical markers of these changes remain elevated for up to 14 days post-treatment, leading to sustained effects (Berger & Jacks, 2014).
The Stimpod is portable, user-friendly, and designed for clinical settings, making it ideal for physiotherapy applications.
How Stimpod Works for CIPN Management
For CIPN, the Stimpod addresses nerve dysfunction by restoring natural signaling and promoting healing.
The electromagnetic field modulates C-fibers—small nerves responsible for pain and sensation—reversing abnormal signals caused by chemotherapy toxins. This can reduce hypersensitivity, improve sensation, and alleviate symptoms like burning and tingling.
At Leading Edge Physiotherapy, with clinics across Alberta and British Columbia, we integrate Stimpod into personalized treatment plans.
- Initial assessment by our physiotherapists evaluates symptoms and confirms suitability.
- During a session, patients sit or lie comfortably while a ground electrode is placed distally, and the probe targets symptomatic areas (e.g., feet or hands).
- Stimulation is adjusted to a tolerable level, often described as a mild pulsing or tingling.
- Each treatment focuses on specific nerves innervating the affected regions, enhancing nerve metabolism and function (Algiamed Technologies, 2024).
Treatment Protocol and Insurance Coverage
- Typical Program: 6–12 sessions, spaced 1–2 times per week, depending on severity.
- Session Length: 5–10 minutes for targeted areas; full appointments may include complementary physiotherapy (20–30 minutes total).
- Cost: Depends on location (please call) and is charged per session (includes device use, therapist expertise, and adjunct therapies).
- Insurance: Most third-party benefits cover physiotherapy services, including Stimpod treatments, under standard PT codes. Our team assists with insurance claims to make care accessible.
Many patients notice relief after 1–5 sessions, with cumulative benefits building over time. Effects can last weeks to months, reducing the need for ongoing treatments. Follow-up sessions may be recommended for maintenance.
Safety and Efficacy: Backed by Evidence
Safety:
- Non-invasive, drug-free therapy.
- No known side effects beyond occasional mild soreness during nerve healing, which resolves quickly.
- No serious adverse events reported in clinical applications (Taverner et al., 2010).
- Suitable for most patients, including those post-chemotherapy, with exceptions such as pacemakers (consult your physician).
Efficacy:
- In diabetic neuropathy, Stimpod induces long-term pain relief by stimulating nerves and modulating inflammation (Hussain et al., 2019).
- Case studies show success in reducing symptoms for diabetic neuropathy, sciatica, and Bell’s palsy, with improvements in mobility and function (Chang et al., 2024).
- CIPN-specific trials of electrotherapies like TENS and HTEMS demonstrate strong results, including significant improvements in sensory symptoms and reductions in CIPN grade (Ewertz et al., 2024; Gewandter et al., 2019).
These findings suggest Stimpod’s PRF mechanism could offer similar or enhanced benefits, as it targets deeper nerve regeneration.
A Path to Relief
Stimpod NMS460 at Leading Edge Physiotherapy represents a safe, effective, and accessible option for managing chemo-induced neuropathy.
By addressing nerve dysfunction at its source, it empowers patients to regain comfort and mobility.
References (abbreviated for space)
- Algiamed Technologies. (2024). Research Section.
- Berger, P., & Jacks, J. (2014). Acupuncture and Related Therapies.
- Chang, Y., et al. (2024). Heliyon.
- Ewertz, M., et al. (2024). Frontiers in Neurology.
- Gewandter, J.S., et al. (2019). Supportive Care in Cancer.
- Hussain, A., et al. (2019). Indian Journal of Pain.
- Taverner, M.G., et al. (2010). Clinical Journal of Pain.
Disclaimer: no information on this page is meant to replace or appear to provide care that is best provided by medical professionals.
